A Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneous REGN 728 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2014
At a glance
- Drugs REGN 728 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 01 Mar 2012 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2012 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 07 Nov 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.